Agents targeting epidermal growth factor receptor (EGFR) are used to treat head and neck squamous cell carcinoma (HNSCC); however, their efficacy and safety is poorly understood. Here we evaluated the efficacy and safety of anti-EGFR agents administered concurrently with standard therapies for HNSCC. Randomized controlled trials that evaluated addition of EGFR targeted therapy versus standard therapy alone were included. The primary outcome was overall survival (OS). Secondary outcomes were progression-free survival (PFS), overall response rate (ORR), locoregional control, and severe adverse events (SAEs, grade 3). Sixteen eligible trials with 4031 patients were included. Addition of anti-EGFR regimens to standard therapy significantly improved OS of patients with HNSCC (HR 5 0.89; 95% CI, 0.82-0.96), with a moderately elevated rate of SAEs (RR 5 1.08; 95% CI, 1.03-1.13). Subgroup analysis indicated that the survival benefit was observed when cetuximab was administered concurrently with radiotherapy (RT) for stage III/IV patients (HR 5 0.76; 95% CI, 0.61-0.94; p 5 0.01), or with chemotherapy for recurrent or metastatic (R/M) HNSCC (HR 5 0.86; 95% CI, 0.78-0.95; p 5 0.005). Significantly increased ORR (RR 5 1.51; 95% CI 1.05-2.18) and PFS (HR 5 0.72; 95% CI, 0.59-0.88) were found in R/M HNSCC patients treated with anti-EGFR plus chemotherapy, while no significant improvements were found in stage III/IV patients treated with anti-EGFR plus standard therapy. In conclusion, addition of cetuximab to standard therapy may improve outcomes for R/M HNSCC patients, while causing a moderate increase in SAEs. For stage III/IV patients, anti-EGFR mAb plus RT can improve OS compared with RT alone, while replacement of chemotherapy with EGFR mAb or adding EGFR mAb to combined chemotherapy and RT did not improve outcomes.
Introduction
Head and neck squamous cell carcinoma (HNSCC) accounts for 95% of head and neck cancer, which can arise in the oral cavity, oropharynx, hypopharynx, or larynx. HNSCC is a leading cause of morbidity and mortality worldwide and accounts for approximately four percent of all cancers in the United States, with an estimated 48,330 new cases and 9,570 deaths in 2016. 1 According to National Comprehensive Cancer Network (NCCN) guidelines for HNSCC, early-stage HNSCC (stage I/II) is usually treated with single modality therapy, i.e., surgery or radiotherapy. The locally or regionally advanced disease requires radiation and/or surgery with the addition of chemotherapy. 2 However, the 5-year relative survival rates for individuals with HNSCC are only 63%, primarily because approximately 80-90% of patients with advanced HNSCC develop loco-regional recurrence or distant metastases. 3 Thus, treatment of patients with advanced HNSCC remains challenging.
Epidermal growth factor receptor (EGFR) is a cell-surface receptor belonging to ErbB family of tyrosine kinase. Overexpression of EGFR is correlated with poor prognosis in cancer due to increased cell proliferation and migration, and inhibition of cancer cells apoptosis. These effects of EGFR were mainly mediated by three key signaling pathways, including Ras/Raf-mitogen-activated protein kinase (MAPK) pathway, phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT pathway, and Janus kinases/signal transducers and activators of transcription (JAK/STAT) pathway . 4, 5 Advances in understanding of the EGFR signaling pathways in cancer have led to the development of anti-EGFR agents including monoclonal antibodies (mAbs) and small-molecule tyrosine kinase inhibitors (TKIs). 6 Anti-EGFR agents have been tested in HNSCC; however, the majority produced conflicting results. [7] [8] [9] [10] Moreover, it remains uncertain whether the risks of adverse effects are higher when anti-EGFR agents are added to standard therapy. 7, [10] [11] [12] Therefore, we conducted a systemic search and analysis of randomized controlled trials (RCT), to evaluate the efficacy and safety of anti-EGFR administered concomitantly with standard therapy for patients with HNSCC.
Evidence Acquisition
This systematic review and meta-analysis was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis and Meta-analysis of Observational Studies in Epidemiology recommendations for study reporting.
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Research question
To assess the efficacy and safety of anti-EGFR antibodies administered concomitantly with standard therapy in patients with HNSCC versus standard therapy alone.
Literature-search strategy
Literature searches of PubMed, Embase, and the Cochrane Library were performed until July 28, 2016, limited to human studies and English-language publications. The main keywords used to search were as follows: head and neck cancer, oropharyngeal cancer, laryngopharyngeal cancer, EGFR inhibitor, cetuximab, panitumumab, nimotuzumab, TKI, gefitinib and erlotinib. A full search strategy is presented in the Supplementary literature-search strategy methods.
Inclusion and exclusion criteria
Only RCT that evaluated addition of anti-EGFR targeted therapy to standard therapy versus the standard therapy alone were included. Conference abstracts were excluded. Where there was more than one publication resulting from the same patient cohort, the most recent or complete report was used to prevent the duplication of data from patients from one cohort.
Data extraction and outcomes of interest
Data from the included studies were extracted and summarized independently by two of the authors (Ym Tian and Yh Tian). Any disagreements were discussed and a third senior author (Rh Zheng) consulted when necessary. Titles and abstracts were used for an initial screen for study inclusion, while full-text review was used when abstracts and titles were insufficient to determine if the study met the inclusion or exclusion criteria. For all eligible trials, the following data were extracted from the selected reports: first author, year of publication, study phase, number of patients (per arm), outcome (overall survival [OS] progression-free survival [PFS] , overall response rate [ORR] , and loco-regional recurrence [LRC]), and severe adverse events (SAEs, grade 3). The primary outcome was OS and secondary outcomes were PFS, ORR, LRC, and SAEs related to combination therapy. Moreover, analyses of various common SAEs between anti-EGFR agents plus standard therapy and standard therapy alone were also performed.
Assessment of risk of bias and statistical analyses
The risk of bias in the present study was evaluated by two independent reviewers (Yh Tian and Ym Tian). Special attention was paid to random sequence generation, allocation concealment, blinding, completeness of outcome data, risk of selective outcome reporting, and risk of other potential sources of bias, which generally represent the quality of RCTs in the procedure for inclusion of trials. 15 We planned to combine risk ratios (RRs) for dichotomous variables and hazard ratios (HRs) for survival data. In the case of enough studies, subgroup analyses of different therapies, including anti-EGFR plus chemotherapy, RT, or CRT, were performed. We also performed a subgroup analysis to assess the impact of different anti-EGFR groups (mAb and TKIs), and different anti-EGFR agents. Begg's funnel and Egger's tests were conducted to detect publication bias. The analyses described above were conducted in Review Manager 5.3 (Cochrane Collaboration, Oxford, UK), except for Begg's funnel and Egger's tests for publication bias, which were performed using STATA version 12.0 (STATA Corp., College Station, TX). The heterogeneity in treatment effects between trials and statistical heterogeneity were assessed using the I 2 statistic and v 2 tests with significance set at P < 0.10. A random-effects model was used if there was heterogeneity between studies; otherwise, fixed-effects models were used. 16 
Results
Selected studies
A total of 4237 references were identified by electronic searches and a further 223 additional references were also found. After the article titles and abstracts were checked, 61 studies were found to be potentially relevant (Fig. 1) . After assessment of the full text, 16 studies were included in the systematic review. [7] [8] [9] [10] 12, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] The characteristics of the selected 16 studies are presented in Table 1 . The papers were published between 2005 and 2016. A total of 4,031 cases were involved in the studies. Overall, after evaluation of the qualities of the 16 included trials, they were considered to be of moderate risk of bias. Fourteen of the included studies were assessed as being at low risk of random sequence generation, nine studies concealed the randomization schedule from the investigators. Eleven studies were assessed as being at low risk of attrition bias. Nine studies were assessed as at low risk for reporting bias. No other sources of bias were identified from these studies.
Overall survival
Finally, 15 articles were included in this meta-analysis. The article reported by Reddy et al. was omitted because the HRs and P values reported in the study for OS and PFS outcomes were inconsistent. Overall, the combined results showed that the addition of anti-EGFR regimens to standard therapy significantly improved the survival of patients (HR 5 0.89; 95% CI, 0.82-0.96; p 5 0.004) (Fig. 2) . Subgroup analyses indicated that the survival benefit was observed when anti-EGFR agents were administered concurrently with radiotherapy (RT) for stage III/IV patients (HR 5 0.76; 95% CI, 0.61-0.94; p 5 0.01), or with chemotherapy for R/M HNSCC (HR 5 0.86; 95% CI, 0.78-0.95; p 5 0.005). However, analyses of the subgroups comparing anti-EGFR plus RT versus CRT, or anti-EGFR plus CRT versus CRT alone, indicated no significant differences in OS between the groups, respectively (Supporting Information Fig. S1A ).
Moreover, subgroup analyses from eleven studies showed that the addition of anti-EGFR mAb to standard therapy significantly improved the OS of patients (HR 5 0.87; 95% CI, 0.80-0.96; p 5 0.003) (Supporting Information Fig. S1B ). However, the results from four studies indicated that there no evidence of a difference in OS between groups receiving a TKI plus standard therapy and groups receiving standard therapy alone. Subgroup analyses also indicated that the addition of cetuximab,but not other agents (panitumumab, nimotuzumab, lapatinib, gefitinib, or erlotinib) to standard therapy significantly improved the OS of patients (HR of 0.83; 95% CI, 0.73-0.94; p 5 0.004) (Supporting Information Fig. S1C ).
Overall response rate
In the present meta-analysis, data for the ORR was derived from ten trials. The combined results, consisting of 2414 eligible patients (1217 vs. 1197 patients), showed that the addition of anti-EGFR regimens to standard therapy significantly increased the ORR of patients (RR 5 1.23; 95% CI 1.03-1.47; p 5 0.02; incidence, 47.6% vs. 38.3%), with significant heterogeneity detected (I 2 5 76%, P < 0.001) (Fig. 3) . As shown in Supporting Information Figure S2A , the results of subgroup analysis indicated that significantly higher ORRs were detected among patients with R/M HNSCC treated by anti-EGFR plus chemotherapy, compared with chemotherapy alone (RR 5 1.51; 95% CI 1.05-2.18; p 5 0.03), while no significant differences were found among patients with stage III/ IV disease. Moreover, the addition of anti-EGFR mAb but not TKI to standard therapy significantly increased the ORR of patients with HNSCC (RR 5 1.30; 95% CI 1.06-1.60; p 5 0.01) (Supporting Information Fig. S2B) . Finally, the results of subgroup analysis demonstrated that ORR was RT1Cetuximab (35) RT1Cisplatin (35) Martins ( 
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significantly increased when nimotuzumab was added to standard therapy, while no significant differences were found when cetuximab, panitumumab, gefitinib, or lapatinib were added (Supporting Information Fig. S2C ).
Progression-free survival and locoregional control
The combined results from twelve studies showed that patients treated with the anti-EGFR plus standard therapy had no significant improvement in PFS (HR 5 0.86; 95% CI, 0.73-1.02; p 5 0.09), with significant heterogeneity among these studies (I 2 5 68%, P < 0.01) (Fig. 4) . Subgroup analysis showed significantly longer PFS was identified among patients with R/M HNSCC treated by anti-EGFR plus chemotherapy than by chemotherapy alone (HR 5 0.72; 95% CI, 0.59-0.88; p 5 0.001), while no significant difference was found in stage III/IV patients treated with standard therapy, with or without anti-EGFR agents (Supporting Information  Fig. S3A ). Moreover, there was no benefit from anti-EGFR when subgroup analyses were performed according to different anti-EGFR groups, or different anti-EGFR agents (Supporting Information Fig. S3B and 3C ).
For analysis of LRC, 1245 patients from six randomized trials were included in this meta-analysis. As shown in Supporting Information Figure S4 , the results indicated that use of anti-EGFR plus chemotherapy was not associated with a significant improvement in LRC (HR 5 1.14; 95% CI, 0.81-1.61; p 5 0.46; I 2 5 69%). Finally, results associated with OS, ORR, PFS and LRC are shown in Supporting Information Table S1 . Table S1 ). These treatment-related SAEs included dysphagia, radiation mucositis, skin reaction, followed by fatigue nausea and hematological toxicity. Subgroup analysis confirmed that significantly more SAEs were observed in patients treated with anti-EGFR plus CRT or chemotherapy, compared with CRT or chemotherapy alone (anti-EGFR plus CRT versus CRT, RR 5 1.08; 95% CI, 1.02-1.14, p 5 0.01; anti-EGFR plus chemotherapy versus chemotherapy alone, RR 5 1.09; 95% CI, 1.01-1.19, p 5 0.03) (Supporting Information Fig. S5A ). Subgroup analyses revealed that significantly more SAEs occurred in the anti-EGFR mAb plus standard therapy than the standard therapy alone groups (RR 5 1.07; 95% CI, 1.02-1.12, p 5 0.008) (Supporting Information Fig. S5B ). Moreover, results indicated that significantly more SAEs occurred when cetuximab was added to standard therapy (RR 5 1.05; 95% CI, 1.01-1.10, p 5 0.02), while no significant difference was found when panitumumab, gefitinib, or erlotinib were added to standard therapy (Supporting Information Fig. S5C ).
Pooled analyses of severe mucositis and radiation dermatitis (grade 3) indicated that the addition of anti-EGFR to standard therapy was associated with increased risk of severe mucositis (RR 5 1.26; 95% CI, 1.04-1.52, p 5 0.02) and radiation dermatitis (RR 5 1.69; 95% CI, 1.41-2.03, P < 0.01) compared with standard therapy alone (Supporting Information Table S2 ). Subgroup analyses confirmed that significantly more mucositis (RR: 1.47; 95% CI, 1.07-2.03, p 5 0.02) and radiation dermatitis (RR: 1.70; 95% CI, 1.32-2.19, P < 0.01) were observed in groups receiving anti-EGFR therapies in addition to CRT. Furthermore, more cases of radiation dermatitis (RR 5 2.16; 95% CI, 1.49-3.12, P < 0.01) were observed when anti-EGFR plus RT was compared with CRT.
Among other SAEs, there was no significant association of the addition anti-EGFR to standard therapy with increased risk of fatigue, dysphagia, anorexia, weight decrease, dehydration, or severe hematological toxicity. Furthermore, electrolyte disequilibrium-related SAEs were analyzed, and the results indicated significantly more severe hypokalemia, and hypocalcemia, but not hyponatremia, in the anti-EGFR plus standard therapy group compared with the standard therapy Table S2 ). Finally, the results indicated that the addition anti-EGFR to standard therapy was associated with higher risk ratio of skin reaction (RR 5 16.73; 95% CI, 9.77-28.66; P < 0.01).
Publication bias and sensitivity analyses
The results of Begg's and Egger's tests indicated that there were no publication biases for OS (Begg's, p 5 0.843; Egger's, p 5 0.195), PFS (Begg's, p 5 0.373; Egger's, p 5 0.363), or ORR (Begg's, p 5 0.213; Egger's, p 5 0.100). In this review, we did not construct funnel plots of LRC due to the limited number of studies reporting this outcome. Begg's funnel plots are presented in Supporting Information Fig. S6 .
In addition, we conducted sensitivity analyses to check the robustness of the results of the meta-analyses of data with high heterogeneity. For PFS, after excluding the studies of Vermorben et al. (2008), we found that I 2 decreased from 76% to 68%; however, the combined HR remained unchanged (HR 5 0.89, 95% CI 0.81-0.98). For ORR, although I 2 did not decrease after excluding each study, we did not identify any significant changes in the pooled estimate, indicating that the results of the meta-analysis were statistically stable and reliable.
Discussion
In this study, we investigated the efficacy and safety of anti-EGFR treatments administered concomitantly with standard therapy for patients with HNSCC. Our results demonstrate that the addition of anti-EGFR regimens to standard therapy significantly improve the survival of patients with late stage or recurrent HNSCC. Further analyses indicate that the addition anti-EGFR mAb (especially cetuximab) to standard therapy can increase PFS, and ORR in individuals with R/M HNSCC, while it was also associated with a higher rate of treatment-related SAEs. However, for stage III/IV patients, only improved OS was observed, with no significant differences in PFS or ORR, after addition of anti-EGFR regimens to RT, compared with RT alone. In HNSCC, anti-EGFR agents have become a regular component of curative therapies, as well as palliative treatment strategies, although with conflicting results. In general, the findings of this meta-analysis indicate that the addition anti-EGFR to standard therapy can significantly increase OS of people with HNSCC. Moreover, both PFS and ORR can be improved by treatment of patients with R/M HNSCC treated anti-EGFR plus chemotherapy in an unselected patient population. This is consistent with previous systematic review and meta-analysis, which showed that adding anti-EGFR mAb to standard therapy may increase OS and PFS of oral and oropharyngeal cancers. 15 Similarly, previous studies also demonstrated that the combination of chemotherapy plus cetuximab is superior to chemotherapy alone in improving OS when used as a first-line treatment for stage III/IV non-small-cell lung cancer (NSCLC). 28 Our results demonstrate that addition anti-EGFR agents to the radiation-cisplatin platform had no significant impact on PFS, OS, or LRC. There may be several reasons for this lack of effect. First, the DNA repair process is must be active in tumor cells for them to be sensitive to agents targeting this process; however, anti-EGFR agents and standard combined treatment agents (e.g., platinum) may have similar mechanisms of inducing radiation sensitivity (i.e., inhibition of repair of DNA damage caused by radiation); therefore, the addition of anti-EGFR agents produces no additional benefit. In this case, combining anti-EGFR treatment with agents with different mechanisms of action, such as docetaxel or gemcitabine, is the logical choice. 12 Another plausible explanation is that anti-EGFR or chemotherapy mainly affects tumor cells, but not the tumor microenvironment. Generally, sensitivity to radiation and chemotherapy can be influenced by both cancer cells and the tumor microenvironment, 29 however, either chemotherapy or anti-EGFR, or both of them plus RT, can kill the majority of tumor cells by increasing expression of radio/chemoresistant molecules. 30 Hence, the addition of chemotherapy to RT maximizes tumor cell killing effects. In this case, the sensitivity of remaining cells to therapy after CRT may only be increased via changes to the tumor microenvironment induced by agents such as those targeting vascular endothelial growth factor. 31, 32 In the present study, we confirmed that the addition of EGFR mAbs, especially cetuximab, to standard therapy resulted in survival benefit in patients with HNSCC. Consistently, previous studies indicated that the addition of EGFR agents to standard therapy can improve survival for patients with advanced pancreatic cancer and KRAS wild-type unresectable colorectal liver-limited metastases. [33] [34] [35] However, the addition of EGFR TKIs to standard therapy did not enhance therapeutic efficacy across all patients with HNSCC. There are several possible reasons for these findings. First, there are pharmacological differences between small molecule inhibitors like TKIs and antibodies. Generally, mAbs bind to the ligand-binding domain in the ectodomain of EGFR, whereas TKIs specifically inhibit EGFR phosphorylation by functioning as ATP analogues and competing with ATP binding within the catalytic domain. 36 Second, TKIs are administered orally and tend to have much shorter half-lives than mAbs. Thus, the sustained drug concentration of TKIs may be insufficient for optimal efficacy when added to standard therapy for patients with HNSCC. 37 Third, the metabolism of erlotinib is induced by smoking, a prevalent risk factor in HNSCC, which may reduce exposure and consequent biologic efficacy of EGFR inhibition. 23 Finally, the identification of biomarkers may help to select patients likely to exhibit excellent responses to treatment with anti-EGFR agents. For example, cancer patients with mutations in EGFR benefit from the use of TKIs. 38 Screening for biomarkers, such as EGFR and p16, has garnered some interest; however, few such markers have been incorporated into clinical practice.
The results indicated that anti-EGFR agents, especially cetuximab, have potential to result in increased SAEs. Increased risks of severe radiation mucositis, radiation dermatitis, skin reactions, and electrolyte abnormalities were identified among patients treated with anti-EGFR plus standard chemotherapy. These results are consistent with those of other studies, which also suggest that anti-EGFR mAb in combination with different chemotherapy regimens is associated with increased incidence of SAEs, including skin rash and electrolyte abnormalities, especially magnesium-wasting syndrome and, for cetuximab, infusion reactions. [39] [40] [41] However, the results of Cui et al. suggest the addition of cetuximab is associated with increased risks of severe leucopenia, neutropenia, and anemia events in colorectal cancer, compared with chemotherapy alone. 42 The difference in severe hematological toxicity between our study and the report of Cui et al. may due to the different proportions of KRAS wild-type patients. 42, 43 Although we performed a comprehensive analysis of the efficacy and safety of anti-EGFR administered concurrently with standard therapy for patients with HNSCC, there were some limitations to this meta-analysis. First, the study size and the sample size for some subgroup analyses were limited, with only 16 RCTs including 4,078 cases available, contributing to the possibility of type I and type II errors. In addition, there is a potential language bias in this meta-analysis because we only considered literature published in English. Second, since this is a systematic review and meta-analysis of the literature, we were only able to extract population-level, rather than individual patient level, data. This limited our ability to assess sources of heterogeneity and also reduced our ability to test for associations between variables in specific subgroups. Third, there was significant heterogeneity in PFS and ORR among the studies included in this analysis. Differences in sample size, patient age, tumor stage and grade, combined therapy, and anti-EGFR agents among the studies may be responsible for the observed high heterogeneity. Fourth, the median follow-up time and survival time for patients varied among the studies; therefore, the HR values for OS, PFS, and LRC were calculated using data from different time points; although this is not ideal, it was the only feasible approach given the data available. Fifth, there were some differences in the tools used for assessment of SAEs. Sixth, quality of life (QOL) which may be as important as the quantity of survival to an individual, was not analyzed in all of these included studies. Finally, the definitions of some AEs overlapped in some studies; for example, mucosis may be associated with either RT or anti-EGFR, while in some studies both of them were listed together.
Despite the limitations of our investigation, this metaanalysis demonstrates that addition of anti-EGFR regimens, especially cetuximab, to standard therapy may increase OS, PFS, and ORR for patients with R/M HNSCC, while contributing to a moderate increase in the rate of SAEs, especially severe mucositis and radiation dermatitis. As we know, SAEs induced by various therapy regimens can reduce patient QOL. Thus, when we consider treatment modality, we should balance the improving prognostic outcomes with long-term QOL. For patients with stage III/IV disease, the addition of anti-EGFR regimens, especially cetuximab, to RT can improve OS compared with RT alone, while replacing chemotherapy with anti-EGFR regimens or adding EGFR mAbs to CRT did not improve outcomes. Future studies to screen for genetic variants or biomarkers that can assist in identification of specific subsets of patients who will obtain optimum benefit from treatment with anti-EGFR mAbs, or to determine clinical outcomes in patients with HNSCC may be promising approaches. Moreover, the long-term impact of the increased SAEs on patient QOL from addition of anti-EGFR agents should be examined in the future.
